IdorsiaXSWX:IDIA +2.56%49 Median PS Value is CHF0.00 as of Jun. 26, 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 49/100 and a GF Value™ of CHF2.85 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 276 Biotechnology companies, Idorsia ranks worse than 362318.48% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Idorsia's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF0.963. Idorsia's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is CHF0.00.
As of today (2026-06-26), Idorsia's share price is CHF6.02. Idorsia's Median PS Value is CHF0.00. Therefore, Idorsia's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Idorsia's Median PS Value or its related term are showing as below:
XSWX:IDIA's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Idorsia (XSWX:IDIA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Idorsia's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
6.02
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia Median PS Value Related Terms
Idorsia Median PS Value Historical Data
* Premium members only.
The historical data trend for Idorsia's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Idorsia's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Idorsia's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Idorsia's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0.963.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (XSWX:IDIA) has a Median PS Value of CHF0.00 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #999999 out of 276 companies in the Biotechnology industry.
Is Idorsia's Median PS Value too high?
Idorsia's current Median PS Value is CHF0.00. Based on the distribution chart, Idorsia ranks #999999 out of 276 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Idorsia has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #999999 out of 276 companies for Median PS Value. This places Idorsia in the lower half of its industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Idorsia and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current Median PS Value is CHF0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.85, compared to a current price of CHF6.02 — trading 111.2% above its estimated fair value. The current Median PS Value is CHF0.00. Idorsia's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Median PS Value is CHF0.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.02 is trading 111.2% above its estimated GF Value™ of CHF2.85.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
Median PS Value: CHF0.00
GF Value™: CHF2.85 vs. price of CHF6.02 (111.2% above fair value)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
49GF Score
Get the complete analysis for XSWX:IDIA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
